Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists
PHILADELPHIA, (August 13, 2013) — GenoSpace, PathGroup and the IP & Science business of Thomson Reuters today announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.
Click Here to read the full article.